This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is in focus as Health and Human Services Secretary Robert F. Kennedy Jr. advocates expanding access to peptide drugs through a regulated marketplace. According to iHeartRadio, citing Reuters, Kennedy said during an Oct. 20 appearance on Fox News that the Trump administration is working to ensure Americans can obtain peptides manufactured in inspected facilities. Acknowledging that the peptides under consideration have not been approved by the Food and Drug Administration (“FDA”) as safe or effective, Kennedy argued that consumers would continue purchasing the products regardless of existing restrictions. His comments highlight growing federal attention to the peptide sector, an area of relevance to Adaptogenics Health.
The administration is advancing an interim access policy that would allow the FDA to exercise enforcement discretion for certain peptides, potentially enabling specialty pharmacies to compound products such as BPC-157 without facing regulatory action. The proposal follows recommendations from an advisory committee to ease restrictions on several peptides despite concerns from FDA scientists about insufficient safety and efficacy data. With the peptide market estimated at $2 billion to $3 billion, the proposed changes could reshape the regulatory landscape for companies operating in the peptide and wellness sectors, including Adaptogenics Health.
About Adaptogenics Health Corp.
Adaptogenics Health Corp. is building a science led company focused on identifying, acquiring, designing and advancing proprietary peptide and small molecule programs. The Company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The Company will continue its existing nutraceutical operations while evaluating GLP 1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.
NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN